# Edwards Lifesciences Corp: overview

EW · NYSE · CIK 1099800 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ew.md) · [Financials](/companies/ew/financials.md) · [Filings](/companies/ew/filings.md) · [Insiders](/companies/ew/insiders.md)

Latest reported revenue: [$1.74bn](/filings/0001099800-26-000043.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 4, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001099800-26-000043).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,354](/filings/0001099800-25-000062.md) | [1,386](/filings/0001099800-25-000005.md) | [1,413](/filings/0001099800-26-000026.md) | [1,532](/filings/0001099800-26-000043.md) | [1,553](/filings/0001099800-25-000062.md) | [1,570 d](/filings/0001099800-26-000009.md) | [1,649](/filings/0001099800-26-000026.md) | [1,741](/filings/0001099800-26-000043.md) |
| Gross margin | % | [80.6%](/filings/0001099800-25-000062.md) | [78.9%](/filings/0001099800-25-000005.md) | [78.7%](/filings/0001099800-26-000026.md) | [77.5%](/filings/0001099800-26-000043.md) | [77.8%](/filings/0001099800-25-000062.md) | [78.1% d](/filings/0001099800-26-000009.md) | [78.0%](/filings/0001099800-26-000026.md) | [77.5%](/filings/0001099800-26-000043.md) |
| Operating margin | % | [25.9%](/filings/0001099800-25-000062.md) | [22.6% d](/filings/0001099800-26-000009.md) | [27.9%](/filings/0001099800-26-000026.md) | [26.8%](/filings/0001099800-26-000043.md) | [19.8%](/filings/0001099800-25-000062.md) | [9.6% d](/filings/0001099800-26-000009.md) | [29.0%](/filings/0001099800-26-000026.md) | [29.5%](/filings/0001099800-26-000043.md) |
| Net margin | % | [226.7%](/filings/0001099800-25-000062.md) | [27.8%](/filings/0001099800-25-000005.md) | [25.3%](/filings/0001099800-26-000026.md) | [21.7%](/filings/0001099800-26-000043.md) | [18.7%](/filings/0001099800-25-000062.md) | [5.8% d](/filings/0001099800-26-000009.md) | [23.1%](/filings/0001099800-26-000026.md) | [13.9%](/filings/0001099800-26-000043.md) |
| Diluted EPS | $ per share | [5.13](/filings/0001099800-25-000062.md) | [0.65](/filings/0001099800-25-000005.md) | [0.61](/filings/0001099800-26-000026.md) | [0.56](/filings/0001099800-26-000043.md) | [0.50](/filings/0001099800-25-000062.md) | not reported | [0.66](/filings/0001099800-26-000026.md) | [0.42](/filings/0001099800-26-000043.md) |
| Free cash flow | $m | [300 d](/filings/0001099800-25-000062.md) | [(177) d](/filings/0001099800-26-000009.md) | [224](/filings/0001099800-26-000026.md) | [241 d](/filings/0001099800-26-000043.md) | [516 d](/filings/0001099800-25-000062.md) | [354 d](/filings/0001099800-26-000009.md) | [(21.1)](/filings/0001099800-26-000026.md) | [585 d](/filings/0001099800-26-000043.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [5,233](/filings/0001099800-24-000004.md) | [4,464](/filings/0001099800-25-000005.md) | [5,010](/filings/0001099800-26-000009.md) | [5,440](/filings/0001099800-26-000009.md) | [6,068](/filings/0001099800-26-000009.md) |
| Gross margin | % | [76.1%](/filings/0001099800-24-000004.md) | [83.8%](/filings/0001099800-25-000005.md) | [80.5%](/filings/0001099800-26-000009.md) | [79.5%](/filings/0001099800-26-000009.md) | [78.0%](/filings/0001099800-26-000009.md) |
| Operating margin | % | [32.3%](/filings/0001099800-24-000004.md) | [33.6%](/filings/0001099800-25-000005.md) | [26.1%](/filings/0001099800-26-000009.md) | [25.3%](/filings/0001099800-26-000009.md) | [20.8%](/filings/0001099800-26-000009.md) |
| Net margin | % | [28.7%](/filings/0001099800-24-000004.md) | [34.1%](/filings/0001099800-25-000005.md) | [28.0%](/filings/0001099800-26-000009.md) | [76.7%](/filings/0001099800-26-000009.md) | [17.7%](/filings/0001099800-26-000009.md) |
| Diluted EPS | $ per share | [2.38](/filings/0001099800-24-000004.md) | [2.44](/filings/0001099800-25-000005.md) | [2.30](/filings/0001099800-26-000009.md) | [6.97](/filings/0001099800-26-000009.md) | [1.83](/filings/0001099800-26-000009.md) |
| Free cash flow | $m | [1,406](/filings/0001099800-24-000004.md) | [974](/filings/0001099800-25-000005.md) | [643](/filings/0001099800-26-000009.md) | [290](/filings/0001099800-26-000009.md) | [1,335](/filings/0001099800-26-000009.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/ew/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $5.32bn | 58,789,433 |  | Added +6,198,500 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $3.40bn | 37,615,952 |  | Reduced −111,840 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $2.39bn | 26,411,402 |  | Added +4,384 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $2.38bn | 26,321,940 |  | Added +25,541 |
| [JPMORGAN CHASE & CO](/funds/19617.md) | 2026-06-30 | $2.08bn | 22,783,175 |  | Added +1,038,463 |
| [WELLINGTON MANAGEMENT GROUP LLP](/funds/902219.md) | 2026-06-30 | $1.52bn | 16,827,967 |  | Reduced −5,183,134 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $1.39bn | 15,437,251 |  | Added +2,303,474 |
| [Bank of New York Mellon Corp](/funds/1390777.md) | 2026-06-30 | $1.27bn | 14,084,483 |  | Reduced −2,653,065 |
| [DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main](/funds/1694217.md) | 2026-06-30 | $1.18bn | 13,002,965 |  | Added +191,063 |
| [Ninety One UK Ltd](/funds/1418329.md) | 2026-06-30 | $1.12bn | 12,337,502 |  | Reduced −58,641 |

## Recent filings

[All 2,132 filings](/companies/ew/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-28 | 20:15 ET | [8-K](/filings/0001099800-26-000048.md) | 5.02 Departure or appointment of officers or directors | 0001099800-26-000048 |
| 2026-08-04 | 20:14 ET | [10-Q](/filings/0001099800-26-000043.md) | Quarterly report, period 2026-06-30 | 0001099800-26-000043 |
| 2026-07-23 | 20:29 ET | [8-K](/filings/0001099800-26-000038.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001099800-26-000038 |
| 2026-05-08 | 20:12 ET | [8-K](/filings/0001099800-26-000028.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001099800-26-000028 |
| 2026-05-06 | 20:12 ET | [10-Q](/filings/0001099800-26-000026.md) | Quarterly report, period 2026-03-31 | 0001099800-26-000026 |
| 2026-05-04 | 20:53 ET | [8-K](/filings/0001099800-26-000023.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure | 0001099800-26-000023 |
| 2026-04-23 | 20:20 ET | [8-K](/filings/0001099800-26-000021.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001099800-26-000021 |
| 2026-03-26 | 20:05 ET | [DEF 14A](/filings/0001099800-26-000015.md) | Proxy statement, period 2026-05-07 | 0001099800-26-000015 |
| 2026-02-25 | 21:11 ET | [10-K](/filings/0001099800-26-000009.md) | Annual report, period 2025-12-31 | 0001099800-26-000009 |
| 2026-02-10 | 21:22 ET | [8-K](/filings/0001099800-26-000006.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001099800-26-000006 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001099800-26-000009.md), filed Feb 25, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/e339ec3e-7bd5-469e-9ccb-7dbf40cef223)

## About the filer

- CIK: 1099800
- Tickers: EW
- Exchange: NYSE
- SIC code: 3842 Orthopedic, Prosthetic & Surgical Appliances & Supplies
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:33 ET. No prices; not investment advice.